Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 09:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Announces Publication of Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Improvements in Rare Brain Tumor in Journal of Clinical Oncology (JCO)

PALO ALTO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private pharmaceutical company, today announced the publication of the Phase 3 STELLAR clinical study results...
November 20, 2025 09:30 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Highlights Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Benefits in Rare Brain Tumor at Society for Neuro-Oncology (SNO) Annual Meeting

– Updated results based on molecular classification and blinded independent central review demonstrate clinically meaningful survival benefits for patients with recurrent grade 3 astrocytoma who were...
November 10, 2025 07:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Announces Oral Presentation of Updated Results With Blinded Independent Central Review from the Phase 3 STELLAR Clinical Trial at the Society for Neuro-Oncology Annual Meeting

PALO ALTO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 STELLAR trial...
February 27, 2025 08:55 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Appoints Jason Levin, Co-founder and COO to President

PALO ALTO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of eflornithine to...
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc.

Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3

– OS and PFS Study endpoints met in large subgroup of patients with recurrent astrocytoma, IDH mutant grade 3 as defined by the 2021 WHO CNS Tumor Classification in Orbus Therapeutics’ Phase 3 STELLAR...
September 06, 2023 09:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Study in Newly Diagnosed Glioblastoma

- The Phase 1 Study will Evaluate Eflornithine in Combination with Temozolomide - PALO ALTO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage...
January 10, 2023 08:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Enters Exclusive License Agreement for Intellectual Property Related to Treatment of Rare Pediatric Syndrome with Eflornithine

PALO ALTO, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage biopharmaceutical company focused on the development and commercialization of therapies that treat...
January 19, 2022 09:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

- Phase 3 STELLAR trial evaluating eflornithine in patients with recurrent anaplastic astrocytoma - - Pre-specified interim analysis to test for superiority expected to occur in 2022 - PALO...
September 28, 2021 10:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine

- Patent relates to method for use of eflornithine to treat cancers, including gliomas - PALO ALTO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private, late-stage...
March 02, 2021 10:00 ET | Source: Orbus Therapeutics, Inc.

Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study

- Independent Data Monitoring Committee recommends continuation of STELLAR study in rare brain cancer - PALO ALTO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Orbus Therapeutics Inc., a private,...